Lucid Capital upgraded INmune Bio (INMB) to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company’s CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune’s pipeline for the upgrade.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
